Accessibility Menu
CERo Therapeutics logo

CERo Therapeutics

(OTC) CERO

Current Price$0.01
Market Cap$491.00K
Since IPO (2021)-100%
5 YearN/A
1 Year-100%
1 Month-46%

CERo Therapeutics Financials at a Glance

Market Cap

$491.00K

Revenue (TTM)

$0.00

Net Income (TTM)

-$20.70M

EPS (TTM)

-$73.30

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.01

Volume

1,502,330

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $13.14

Estimated Earnings Date

Sep 2, 2026

CERO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CERo Therapeutics

Industry

Biotechnology

Employees

8

CEO

Christopher B. Ehrlich, MBA

Headquarters

South San Francisco, CA 94080, US

CERO Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

2%

Return on Assets

-9%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$491.00K

Shares Outstanding

45.11M

Volume

1.50M

Avg. Volume

749.94K

Financials (TTM)

Gross Profit

-$1.09M

Operating Income

-$18.46M

EBITDA

-$17.38M

Operating Cash Flow

-$16.08M

Capital Expenditure

$0.00

Free Cash Flow

-$16.08M

Cash & ST Invst.

$1.66M

Total Debt

$699.11K

CERo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$276.14K

-2.5%

Gross Margin

0.00%

N/A

Market Cap

$491.00K

N/A

Market Cap/Employee

$61.38K

N/A

Employees

8

N/A

Net Income

-$5.89M

-15.3%

EBITDA

-$4.57M

+5.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$857.49K

-83.5%

Total Debt

$598.35K

-56.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$136.77K

-70.4%

Short Term Debt

$461.58K

-74.5%

Return on Assets

-9.39%

N/A

Return on Invested Capital

2.01%

N/A

Free Cash Flow

-$2.76M

+37.9%

Operating Cash Flow

-$2.76M

+37.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XRTXXORTX Therapeutics Inc.
$2.09-2.79%
PTIXProtagenic Therapeutics, Inc.
$0.41+0.00%
BCTXZBriaCell Therapeutics Corp. Warrant
$0.08-0.25%
ELABPMGC Holdings Inc.
$1.39-2.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$185.00-0.04%
NOKNokia
$13.49-0.02%
AALAmerican Airlines Group
$15.99+0.04%
PFEPfizer
$25.21-0.03%

Questions About CERO

What is the current price of CERo Therapeutics?

CERo Therapeutics is trading at $0.01 per share.

What is the 52-week range for CERo Therapeutics?

Over the past 52 weeks, CERo Therapeutics has traded between $0.01 and $13.14.

How much debt does CERo Therapeutics have?

As of the most recent reporting period, CERo Therapeutics reported total debt of $598.35K.

How much cash does CERo Therapeutics have on hand?

CERo Therapeutics reported $857.49K in cash and cash equivalents in its most recent financial results.

What is CERo Therapeutics’s dividend yield?

CERo Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.